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Abstract Tau in Alzheimer neurofibrillary tangles has been
shown to be hyperphosphorylated and CDK5, GSK3, MAP
kinase and SAP kinases are the candidate kinases for the
phosphorylation of tau. Recently, it was reported that the
conversion of p35, the activator of CDK5, to p25 was
upregulated in Alzheimer’s disease (AD) brains, and that p35 is
cleaved to yield p25 by calpain. Here we show that p35 is rapidly
cleaved to p25 in rat and human brains within a short
postmortem delay and that the conversion of p35 to p25 is
partially dependent on calpain activity. Immunoblot analysis of
brains prepared from patients with AD or age-matched control
individuals with a short postmortem delay revealed no specific
increase in the levels of p25 in AD brains, whereas the levels of
active form of calpain were increased in AD brains compared to
the those in controls. These observations suggest that the
conversion of p35 to p25 is a postmortem degradation event
and may not be upregulated in AD brains. ß 2001 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
Abundant neuro¢brillary lesions and senile plaques are the
neuropathological hallmarks of Alzheimer’s disease (AD).
Neuro¢brillary lesions are composed of ¢lamentous struc-
tures, paired helical ¢laments (PHFs) and the related straight
¢laments, and hyperphosphorylated microtubule-associated
protein tau (PHF-tau) is the major component of the PHFs
[1^3]. Aggregation of hyperphosphorylated tau is also central
to a number of other dementia disorders [4,5]. Extensive pro-
tein chemical and immunochemical studies have identi¢ed
about 20 hyperphosphorylated amino acid residues in PHF-
tau [6^8], and approximately half of these sites are serine/
threonine-proline sequences. Based on in vitro experiments,
mitogen-activated protein (MAP) kinase [9], neuronal cdc2-
like kinase (NCLK) or CDK5 [10,11], glycogen synthase ki-
nase-3 (GSK3) [12,13], and stress-activated protein kinases
(SAPKs) [14,15] are known as candidate protein kinases for
the hyperphosphorylation of tau. It has recently been shown
that p25, a truncated form of CDK5 activator p35, is upregu-
lated and accumulated in neurons in AD brains [16] and that
the expression of the p25-CDK5 complex induces cytoskeletal
disruption and neurodegeneration in cultured neurons [16]. It
has also been shown that p35 can be cleaved to p25 by calpain
in vitro and in vivo [17,18]. Although calpain has been shown
to be activated in AD brains [19], correlation between the p35
processing and calpain activation is unknown.
We investigated here cleavage of p35 to p25 and activation
of calpain in AD and control brains, and in rat brains with
various postmortem incubation. We show that calpain is
surely activated in AD brains. We also show that p35 is de-
graded to produce p25 in rat brains within a few hours of
postmortem incubation and that the conversion of p35 to p25
is mediated by calpain. Notably, we observed no di¡erence in
the relative levels of brain p25 between AD and age-matched
controls.
2. Materials and methods
2.1. Antibodies
A polyclonal antibody to p25Wp35 (C19) and a polyclonal antibody
to CDK5 (C8) were purchased from Santa Cruz Biotechnology Inc. A
polyclonal antibody to W-calpain, which speci¢cally recognizes the
active form of human W-calpain (76-kDa post-autolytic W-calpain),
and a polyclonal antibody to spectrin are described previously
[20,21]. A monoclonal antibody AT8 is a previously described phos-
phorylation-dependent anti-tau antibody [22]. Antibodies were diluted
at the following ratios: p25Wp35 (C19) (1:1000), CDK5 (C8) (1:1000),
W-calpain (1:500), spectrin (1:500), AT8 (1:1000) for immunoblotting
of brain extracts.
2.2. Preparation of brain extracts from the brains of patients with AD
and age-matched control individuals
Frozen brain tissues with a short postmortem delay (range: 1^6.5 h)
from patients with AD (eight cases, Table 1) and age-matched con-
trols (nine cases, Table 1) were homogenized in four volumes of ex-
traction bu¡er (50 mM Tris pH 7.5, 150 mM NaCl, 1% Triton X-100,
10% glycerol, 5 mM EDTA, 1 mM EGTA, 1 mM DTT, plus protease
inhibitors and phosphatase inhibitors; see [16]), and centrifuged at
13 000Ug for 30 min. The resulting supernatants were used as brain
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extracts. We paid special attention to keep the w/v ratio of wet brain
tissue/extraction bu¡er exactly at 1:4.
Sarkosyl-insoluble fractions were prepared from the ¢rst pellet of
brain homogenates by extracting with 10 volumes of 50 mM Tris
bu¡er (pH 7.5) containing 5 mM EDTA, 0.8 M NaCl, 10% sucrose
and 1% Sarkosyl, followed by incubation at 37‡C for 1 h. Following
centrifugation, the pellets were resuspended in SDS sample bu¡er.
2.3. Preparation of rat brain extracts
10-week-old Wistar rats (Japan-SLC) were lethally anesthetized and
the brains were excised at 0, 1, 3, 6, 14 and 24 h after anesthetization.
Rats were kept at room temperature prior to brain excision. The
brains were homogenized as described in Section 2.2.
To inhibit calpain activation in postmortem rat brains, rats were
anesthetized and perfused transcadially with PBS, PBS plus 10 mM
EGTA or PBS plus 60 WM calpain inhibitor I, and the brains were
subsequently excised at 3 or 6 h after perfusion.
2.4. SDS^PAGE and immunoblotting
SDS^PAGE was performed using 12.5% polyacrylamide gels for
immunoblotting of p25Wp35 and CDK5, 10% gels for tau protein or
7.5% gels for W-calpain and spectrin. For immunoblotting, about 100
Wg proteins were loaded in each lane and transferred to Immobilon P.
The blots were incubated with primary antibodies, followed by per-
oxidase-conjugated anti-mouse or rabbit IgG antibodies (Dako) as
described [17]. The reactions were detected using the ECL Western
blotting systems (Amersham-Pharmacia Biotech, Tokyo, Japan). Rel-
ative intensities of immunolabelled bands were quanti¢ed using Lu-
minescent image analyzer LAS-1000plus (Fuji Film Co.). The inten-
sities of the immunoreactive bands were always within the linear
ranges.
3. Results
3.1. p25 level is not increased in AD brains
To investigate whether the p35 processing and calpain acti-
vation are correlated in AD brains, we collected control and
AD brain tissues with relatively short postmortem intervals
(6 6.5 h) which had been preserved in good condition without
any freeze^thaw processes (Table 1). We then extracted pro-
teins with the extraction bu¡er containing EGTA and pro-
tease inhibitors. The frozen brains used in this study are listed
in Table 1. As shown in Fig. 1A, hyperphosphorylated PHF-
tau was detected in Sarkosyl-insoluble fractions of all AD
brains with a phosphorylation-dependent tau antibody AT8,
whereas no immunoreactivities were seen in control brains,
showing that all AD patients had tau pathology. Immunoblot
analysis of brain extracts with a p25Wp35 antibody showed no
signi¢cant di¡erence in the ratios of p25 to p35 between con-
trol and AD brains (Figs. 1B and 2A), although total levels of
both p25 and p35 were decreased by about 50% in AD brains
compared with those in normal controls. The levels of CDK5
immunoreactivities were also reduced by approximately 50%
in AD brains compared with those in control brains (Fig. 1C).
Because calpain has been implicated in the conversion of
p35 to p25 [17,18], we investigated whether calpain is acti-
vated in AD brains using an antibody which speci¢cally rec-
ognizes the active form of W-calpain [20]. As shown in Fig.
1D, the W-calpain antibody speci¢cally labelled the active form
of calpain which migrated at 76 kDa in human brain extracts,
and the immunoreactivities detected in AD brains were about
7-fold stronger than those in control brains (Figs. 1D and 2B).
Fig. 2 shows quanti¢cation of the p25/p35 ratio and the band
intensities of the active form of W-calpain in AD and control
brains.
Fig. 1. Immunoblots of Sarkosyl-insoluble pellets with anti-tau anti-
body AT8 (A), and brain extracts with anti-p25Wp35 antibody (B),
anti-CDK5 antibody (C) or anti-W-calpain antibody (D) from con-
trol and AD brains. lanes 1^9: brain extracts from control brains;
lanes 10^17: brain extracts from AD brains.
Table 1
Age at death, sex, and postmortem interval (PMI) of control and
AD brains used in this study
Case no Age Sex PMI (h)
Control
1 74 M 3.00
2 83 F 3.83
3 75 M 2.33
4 78 F 3.50
5 83 M 2.50
6 67 F 2.50
7 78 F 1.00
8 80 M 1.00
9 71 M 1.50
AD
10 83 F 6.50
11 83 M 2.50
12 86 F 3.00
13 87 F 2.50
14 71 F 2.17
15 79 M 3.67
16 86 F 3.00
17 83 F 2.67
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3.2. Degradation of p35 in situ
Immunoblot analysis of human brain tissues with various
postmortem delay revealed a marked variation in the levels of
p25 or p35. This prompted us to hypothesize that this varia-
tion might be due to postmortem changes (e.g. postmortem
delay and/or di¡erence in agonal conditions). To investigate
the e¡ect of postmortem delay on p35 protein degradation, we
examined the amount of p25 in rat brains with di¡erent post-
mortem intervals by leaving the sacri¢ced rats at room tem-
perature for 1, 3, 6, 14 and 24 h. As shown in Fig. 3A, p35
was rapidly degraded during incubation at room temperature
after death. At 0 h, i.e. when the brain was immediately ex-
cised and homogenized within a few minutes after death, a
strong p35 band and a very weak p25 band were detected.
During postmortem incubation of 3^14 h, the levels of p35
band gradually decreased, whereas those of p25 in turn in-
creased. The intensity of p25 band reached maximum at 14 h
and then slightly decreased at 24 h. Fig. 3B shows quanti¢ca-
tion of the band intensities of p25 during postmortem incu-
bation.
To further characterize p35 degradation in situ in postmor-
tem rat brain, we analyzed calpain activation in brains by
detecting spectrin degradation with an anti-spectrin antibody
that speci¢cally detects the cleavage site by calpain [21]. Spec-
trin (full-length, 230 kDa) has been shown to be cleaved by
calpain to generate a 150-kDa fragment, which has been re-
garded as an indicator of calpain activation. A very weak 150-
kDa fragment was detected in rat brain extract at 0 h of delay.
Then the 150-kDa band gradually increased at 1, 3, 6 h after
death, suggesting activation of calpain during postmortem
incubation (Fig. 3C,D). The levels of the 150-kDa spectrin
fragment during postmortem incubations were closely corre-
lated with those of p25 (Fig. 3B,D).
To obtain further evidence for the calpain-dependent deg-
radation of p35 in postmortem rat brains, we perfused rat
brains with a calcium-chelating bu¡er or a bu¡er containing
a calpain inhibitor peptide, and incubated for 3^6 h prior to
preparation of brain samples. Interestingly, degradation of
p35 was signi¢cantly inhibited by this treatment (Fig. 4A,B).
These results strongly suggest that p35 is converted to p25
within several hours of postmortem interval and that calpain
is at least partially involved in this process.
4. Discussion
In this study, we have shown that the levels of p25 in AD
brains with relatively short postmortem intervals were not
increased compared with those in age-matched controls. We
also have shown that the total levels of p25Wp35 and CDK5
were decreased by about 50% in AD brains in which hyper-
phosphorylated PHF-tau was accumulated, and W-calpain was
activated. We investigated the degradation of p35 to p25 dur-
ing postmortem incubation in rat brains and showed that the
conversion of p35 to p25 was rapid and partially mediated by
calpain.
Fig. 3. A: Immunoblots of brain extracts from rats with di¡erent
postmortem intervals with anti-p25Wp35 antibody (C19). B: Time
course of degradation of p35 (a) and production of p25 (b) in
postmortem rat brains. C: Immunoblots of brain extracts from rats
with di¡erent postmortem intervals with anti-spectrin antibody. D:
Time course of production of the 150-kDa spectrin fragment in
postmortem rat brains. Intensities of immunolabelled bands were
quanti¢ed using a Luminescent image analyzer.
Fig. 2. A: p25/p35 ratios in control and AD brains. B: Levels of
the active form of 76-kDa W-calpain in control and AD brains. Rel-
ative intensities of immunolabelled bands were quanti¢ed using a
Luminescent image analyzer. The intensities of the immunoreactive
bands were always within the linear ranges. *P6 0.05.
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Our present results are not consistent with those by Patrick
et al. [16], in which the level of p25 was shown to be 20^40-
fold upregulated in AD brains, whereas the p35 levels re-
mained unchanged, suggesting that the p25 protein is accu-
mulated in the tangle-bearing neurons of AD brains [16]. We
are not certain about the reasons why they detected increased
levels of p25 in AD brains. We prepared brain extracts exactly
according to their method with the same bu¡er as they used.
The di¡erence in the speci¢cities of the antibodies used to
detect p25Wp35 proteins might have a¡ected the results to
some extent.
However, it also might be due to di¡erence in postmortem
delays of brain tissues. As we have shown here, postmortem
intervals signi¢cantly a¡ected the levels of p25 and p35. By
immunoblot analysis of rat brains with various controlled
postmortem delays, we have shown that p35 degraded to
p25 during 1^6 h of postmortem incubation and that the
levels of p25 were drastically increased within a few hours
of postmortem intervals. The freeze^thaw process also in-
creased the levels of p25 or p35 in tissues, probably because
conversion of p35 to p25 is stimulated by a treatment that
damages cells and activates calpain (data not shown). Several
previous reports also have shown that p35, but not p25, pre-
dominates in the crude brain extracts [23^25], whereas the
p35^CDK5 complex has never been puri¢ed from mammalian
brains [26,27], probably because p35 degrades to p25 by cal-
pain during puri¢cation.
Several studies have shown that the CDK5^p35 complex is
involved in the migration or positioning of neural cells
through phosphorylation of cytoskeletal proteins during de-
velopment [28,29], and tau and neuro¢laments (NF-H and
NF-M) [26,30] have been identi¢ed as substrates for this com-
plex. The CDK5^p25 complex has also been puri¢ed from
microtubule-enriched fractions of bovine and porcine brain
extracts [26,27]. In neurons of AD brains, tau becomes hyper-
phosphorylated and microtubules are disrupted and replaced
by the abnormal tau ¢laments, i.e. PHFs. The levels of CDK5
and p25Wp35 may be decreased in degenerating neurons of AD
brains as a result of these cytoskeletal changes.
Using a speci¢c antibody to active form of W-calpain, we
have shown that the activation of W-calpain was elevated in
AD brains. This con¢rmed the previous observations by Saito
et al. [19] in which the ratio of active form of W-calpain to the
precursor form was elevated in AD but not in Huntington
disease brains. Although calpain is shown to be able to cleave
p35 to p25 in vitro and in vivo, we could not see any di¡er-
ence in the p25/p35 ratios between control and AD brains.
These contrast to those seen in postmortem rat brains where
the p35 degradation is closely correlated with W-calpain acti-
vation. The reason for this discrepancy is unclear at present;
however, one possibility would be that p25 detected in autop-
sied control and AD brains is largely derived by postmortem
degradation. Further studies in autopsied and biopsied brain
samples as well as in model animals will help to clarify
whether p25 levels are upregulated in AD brains due to cal-
pain activation.
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